Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis

Peng Wang; Jing Ni; Ya-Ya Chu; Qing-Qing Chen; Guo-Cui Wu; Yang Fang; Cong Chen; Ruo-Di Zhang; Ling-Qiong Jiang; Yan Zhao; Xi Fang; Jun He; De-Guang Wang; Gui-Hong Wang; Hai-Feng Pan

Biomedicine & Pharmacotherapy (Jun 2022)

Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis

Peng Wang,
Jing Ni,
Ya-Ya Chu,
Qing-Qing Chen,
Guo-Cui Wu,
Yang Fang,
Cong Chen,
Ruo-Di Zhang,
Ling-Qiong Jiang,
Yan Zhao,
Xi Fang,
Jun He,
De-Guang Wang,
Gui-Hong Wang,
Hai-Feng Pan

Affiliations

Peng Wang: Teaching Center for Preventive Medicine, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei 230016 Anhui, China
Jing Ni: Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei 230016, Anhui, China
Ya-Ya Chu: Wannan Medical College, 22 Wenchang West Road, Wuhu, 241002 Anhui, China
Qing-Qing Chen: Anhui Provincial Center for Disease Control and Prevention, Fanhua Avenue, 12560 Hefei, China
Guo-Cui Wu: School of Nursing, Anhui Medical University, 15 Feicui Road, Hefei, Anhui, China
Yang Fang: Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei 230016, Anhui, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, 81 Meishan Road, Hefei 230016 Anhui, China
Cong Chen: Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei 230016, Anhui, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, 81 Meishan Road, Hefei 230016 Anhui, China
Ruo-Di Zhang: Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei 230016, Anhui, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, 81 Meishan Road, Hefei 230016 Anhui, China
Ling-Qiong Jiang: Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei 230016, Anhui, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, 81 Meishan Road, Hefei 230016 Anhui, China
Yan Zhao: Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei 230016, Anhui, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, 81 Meishan Road, Hefei 230016 Anhui, China
Xi Fang: Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei 230016, Anhui, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, 81 Meishan Road, Hefei 230016 Anhui, China
Jun He: Anhui Provincial Center for Disease Control and Prevention, Fanhua Avenue, 12560 Hefei, China; Public Health Research Institute of Anhui Province, Fanhua Avenue, 12560 Hefei, Anhui, China
De-Guang Wang: Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei, Anhui 230601, China; Corresponding authors.
Gui-Hong Wang: Department of Rheumatology, Anqing Hospital Affiliated to Anhui Medical University, 352 Renmin Road, Anqing, Anhui 246004, China; Corresponding authors.
Hai-Feng Pan: Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei 230016, Anhui, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, 81 Meishan Road, Hefei 230016 Anhui, China; Coresponding author at: Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui 230032, China.

Journal volume & issue: Vol. 150
p. 112997

Abstract

Read online

Background: This study aimed to investigate the seroreactivity of Coronavirus disease 2019 (COVID-19) vaccination and its adverse events among systemic lupus erythematosus (SLE) patients, rheumatoid arthritis (RA) patients, and healthy controls (HCs). Methods: A total of 60 SLE patients, 70 RA patients and 35 HCs, who received a complete inactivated COVID-19 vaccine (Vero cells) regimen, were recruited in the current study. Serum IgG and IgM antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) were determined by using chemiluminescent microparticle immunoassay (CMIA). Results: There were no significant differences regarding the seroprevalences of IgG and IgM antibodies against SARS-CoV-2, and the self-reported vaccination-related adverse events among SLE patients, RA patients and HCs. The inactivated COVID-19 vaccines appeared to be well-tolerated and moderately immunogenic. In addition, case-only analysis indicated that in SLE patients, the disease manifestation of rash and anti-SSA autoantibody were associated with seroprevalence of IgG antibody against SARS-CoV-2, whereas the uses of ciclosporin and leflunomide had influence on the seroprevalence of IgM antibody against SARS-CoV-2. In RA patients, rheumatoid factor (RF) appeared to be associated with the seroprevalence of IgG antibody against SARS-CoV-2. Conclusion: Our study reveals that the seroprevalences of IgG and IgM antibodies against SARS-CoV-2 and vaccination-related adverse effects are similar among SLE, RA and HCs, suggesting that COVID-19 vaccine is safe and effective for SLE and RA patients to prevent from the pandemic of COVID-19.

Published in Biomedicine & Pharmacotherapy

ISSN: 0753-3322 (Print); 1950-6007 (Online)
Publisher: Elsevier
Country of publisher: France
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: https://www.journals.elsevier.com/biomedicine-and-pharmacotherapy

About the journal

Abstract

Keywords